JAMP Pharma Group acquires pharmaceutical manufacturing facility in Lévis, Quebec

JAMP Pharma Group recently announced that it has acquired the assets of Pharmalab’s manufacturing facility in Lévis, Que. The company ceased operations in August 2023. The purchase is subject to Superior Court approval and the fulfillment of customary closing conditions.

“For several years, healthcare professionals and patients have had to deal with inventory shortages. Our ambition was to bolster the local manufacturing capacity to facilitate access to affordable medicine and healthcare solutions. This is a significant milestone for Quebec and Canada. In addition to positively contributing to the creation of wealth in Quebec, JAMP Pharma Group becomes one of the largest Canadian-owned pharmaceutical companies,” stated Louis Pilon, president and CEO of JAMP Pharma Group.

JAMP Pharma Group stated that it plans to relaunch the manufacturing operations of the Levis-based plant “when governments, customers, and partners are calling for more local procurement solutions.”

The company stated that the acquisition will strengthen the Canadian supply chain and assist in addressing drug shortages like those experienced during the COVID-19 coronavirus pandemic. JAMP Pharma Group stated that it plans on hiring a “significant portion” of Pharmalab’s 250 former employees. The company currently has a workforce of more than 700 employees.

“This recent acquisition by JAMP Pharma Group demonstrates its leadership in the Canadian generic drug industry and its commitment to the economic development of Quebec. Fonds de solidarité FTQ is proud to have supported the growth of this Canadian flagship since 2016 and continues to support the company in its future endeavours,” stated Patrice Jolivet, vice-president, investments, for Agri-Food and Health at Fonds de solidarité FTQ, a partner of JAMP Pharma Group.